Form 4: Vir Biotechnology Executive Sells Shares to Cover Tax Obligations

Ann M. Hanly, EVP & Chief Technology Officer of Vir Biotechnology, sold 2,711 shares of common stock on April 1, 2024, to cover tax obligations related to vesting restricted stock units.

Summary

• On April 1, 2024, Ann M. Hanly, the EVP & Chief Technology Officer of Vir Biotechnology, sold 2,711 shares of the company's common stock.
• The sale was executed at a price of $10.052 per share.
• The transaction was an automatic sale to cover the issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
• Following the transaction, Hanly directly owns 132,069 shares of Vir Biotechnology.
• Hanly also indirectly owns shares through her spouse for the benefit of a minor child; the amount is listed as 11.52 shares.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (sale of shares to cover tax obligations). It doesn't indicate any significant positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This transaction is related to tax obligations from vesting of restricted stock units, which is a common occurrence.

Key Dates